Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs will release its financial and operating results for the half year ended 31 December 2025 on 16 February 2026 and will brief investors via a Zoom webinar hosted by CEO Melinda McGrath and CFO Matt Cordingley. The company will provide a recording of the session on its investor website and has outlined how it will collect and handle participants’ personal information for the event in line with its privacy policy, underscoring its ongoing engagement with shareholders and the broader investment community.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited is a leading Australian private provider of pathology services, operating NATA-accredited laboratories that conduct a wide range of tests for doctors, specialists, patients, hospitals and corporate clients. It is one of the largest private hospital pathology businesses nationally, focused on combining clinical expertise with innovative technologies to support better patient outcomes.
Average Trading Volume: 570,144
Technical Sentiment Signal: Sell
Current Market Cap: A$520.9M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.